ProCE Banner Activity

CME

New Insights in Breast Cancer: Independent Conference Coverage of SABCS 2019

Conference Coverage
Text Module
Review the most clinically relevant data presented at CTRC-AACR SABCS 2019 across multiple settings with this set of CME-certified expert commentaries, including advances in HER2-positive and hormone receptor–positive/HER2-negative disease, and in chemotherapy-based treatment strategies.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: March 02, 2020

Expiration: March 01, 2021

No longer available for credit.

Share

Faculty

Sara Hurvitz

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Sara M. Tolaney

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Associate Director, Susan F. Smith Center for Women’s Cancers
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Daiichi Sankyo, Inc.

Genentech TEXT Only

Merck Sharp & Dohme Corp.

Puma Biotechnology, Inc.

Seagen

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with breast cancer
  • Identify subpopulations of patients with breast cancer most likely to benefit from a specific treatment plan based on prognostic or predictive markers
  • Discuss new data on novel agents and therapeutic approaches for patients with early-stage and metastatic breast cancer
  • Consider how new trial findings might affect treatment of breast cancer clinical practice in the future

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosure

Primary Author

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Sara Hurvitz, MD, FACP, has disclosed that she has received funds for research support from Ambrx, Bayer, Daiichi-Sankyo, Dignitana, Genentech/Roche, GlaxoSmithKline, Immunomedics, Lilly, MacroGenics, Novartis, OBI Pharma, Pfizer, Pieris, Puma, Radius, Sanofi, and Seattle Genetics and consulting fees from Pfizer and Roche.

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Associate Director, Susan F. Smith Center for Women’s Cancers
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Sara Tolaney, MD, MPH, has disclosed that she has received funds for research support paid to her institution from AstraZeneca, Bristol-Myers Squibb, Cyclacel, Eisai, Exelixis, Genentech/Roche, Immunomedics, Lilly, Merck, Nektar, Novartis, Odonate, Pfizer, and Sanofi and consulting fees from AbbVie, AstraZeneca, Athenex, Bristol-Myers Squibb, Celldex, Daiichi-Sankyo, Eisai, Genentech, Immunmedics, Lilly, Merck, NanoString, Nektar, Novartis, Pfizer, Pumu, Sanofi, and Seattle Genetics.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael Andrie, PhD, has no relevant conflicts of interest to report.

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Jason J. Everly, PharmD

Jason Everly, PharmD, BCOP, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 02, 2020, through March 01, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve learners’ understanding of how to optimally apply recent practice-changing findings in the treatment of patients with breast cancer.